UNSPSC 51434207: Vincamine hydrochloride

This classification denotes a cns stimulant C21H26N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X9XM85R7QQ, chemically known as (3.alpha.,14.beta.,16.alpha.)-14,15-dihydro-14-hydroxyeburnamenine-14-carboxylic acid methyl ester hydrochloride, but more generally known as vincamine hydrochloride, which bears US NIH Compound Identifier 165895. European Medicines Agency schedules Vincamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05099MIG.

Most nations, for tariff and trade purposes, schedule vincamine hydrochloride under HS 29399900 and SITC 54149. As of Q4 2014, VINCAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@@]12CCCN3[C@@H]1C4C(C5CCCCC5N4[C@](C2)(C(=O)OC)O)CC3.CL.

UNSPSC 51434207 Vincamine hydrochloride is a Commodity code encompassing the supply of specific pharmaceutical compounds to state and local government health agencies, emergency services, and public health systems. Recent state and local solicitations under this code reflect procurement of advanced life support medications and generic pharmaceuticals for use by fire rescue departments, health and human services agencies, and multistate cooperative purchasing consortiums. The City of Tampa's sealed-bid solicitation for Advanced Life Support Medications (Bid No. 26-P-00188) exemplifies the scope: Tampa Fire Rescue requires labetalol, epinephrine, adenosine, and diltiazem vials supplied within ten calendar days of order, with nine-month minimum expiration dates and one-year warranty coverage. Issuing bodies include municipal fire departments, state health agencies, and multistate cooperative purchasing alliances (such as the Minnesota Multistate Cooperative Purchasing Alliance), with procurement coordinated through city purchasing departments and state administration offices. Set-aside programs vary by jurisdiction; Tampa's solicitation includes a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount, while multistate cooperative procurements typically do not specify disadvantaged-enterprise restrictions.

Recent activity spans Florida, Texas, Minnesota, and Oregon, with the most visible current opportunity being Tampa's April 2026 IFB for emergency medications closing April 8, 2026, with an estimated contract value of $40,000. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription programs, signaling upstream interest in pharmaceutical supply-chain restructuring at the state level. The Minnesota Department of Administration's MMCAP RFP, posted January 20, 2026 with proposals due March 26, 2026, sought generic multi-source pharmaceuticals and OTC products for distribution across state and local facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026. Vendors supplying under this code must maintain compliance with cGMP, the Drug Supply Chain Security Act, FDA requirements, and OSHA Hazard Communication Standards, with pricing typically weighted heavily (75 percent in the MMCAP evaluation) and contract terms ranging from one to two years with optional renewal periods.